Stockscreener 앱 받기
159.51
0.16%
-0.25
시장 영업 전:
160.00
0.49
+0.31%
전일 마감가:
$159.76
열려 있는:
$159.89
하루 거래량:
1.24M
Relative Volume:
1.07
시가총액:
$16.04B
수익:
$3.10B
순이익/손실:
$668.60M
주가수익비율:
24.52
EPS:
6.5044
순현금흐름:
$831.30M
1주 성능:
-2.21%
1개월 성능:
+0.69%
6개월 성능:
+3.54%
1년 성능:
+28.23%
1일 변동 폭
$156.70
$160.55
1주일 범위
$156.70
$169.39
52주 변동 폭
$122.14
$169.57
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
159.51 | 16.04B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate - ChartMill
Neurocrine presents case study on Crenessity for rare CAH subtype By Investing.com - Investing.com Australia
Neurocrine presents long-term data on Prader-Willi drug By Investing.com - Investing.com Australia
Neurocrine presents case study on Crenessity for rare CAH subtype - Investing.com
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY - StreetInsider
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 - PR Newswire
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now? - Insider Monkey
Neurocrine presents 2-year Crenessity data at ENDO 2026 By Investing.com - Investing.com South Africa
Neurocrine (NBIX) Reports Positive Phase 3 Data on Crenessity - GuruFocus
Neurocrine reports positive 2-year pediatric CAH data - grafa.com
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH - The Pharma Letter
Neurocrine presents 2-year Crenessity data at ENDO 2026 - Investing.com UK
Neurocrine Biosciences Presents New Two-Year CRENESSITY Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults With Classic Congenital Adrenal Hyperplasia - marketscreener.com
Neurocrine presents two-year pediatric data for Crenessity - Investing.com
Neurocrine presents two-year CRENESSITY data showing growth improvements - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - PR Newswire
Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Investor Outlook Highlights 20.73% Potential Upside - DirectorsTalk Interviews
How New INGREZZA TD Data in Underserved Patients Could Shape Neurocrine Biosciences’ (NBIX) Investment Story - simplywall.st
Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - simplywall.st
Neurocrine Biosciences (NBIX) beats Q1 earnings and revenue estimates - MSN
INGREZZA Data In Complex Patients Adds Support For Neurocrine Valuation Story - simplywall.st
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys - Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy - ChartMill
Neurocrine Biosciences(NBIX.US) Director Sells US$4.13 Million in Common Stock - Moomoo
Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock - Investing.com UK
Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock By Investing.com - Investing.com Canada
Neurocrine (NBIX) director exercises 25K options and sells 25K shares under 10b5-1 plan - Stock Titan
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09 - marketscreener.com
Neurocrine Biosciences (NBIX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Cerebral Palsy Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - Barchart.com
Neurocrine presents tardive dyskinesia treatment data at conference - StreetInsider
Neurocrine Biosciences director sells $210,071 in stock By Investing.com - Investing.com South Africa
Neurocrine Biosciences director sells $210,071 in stock - Investing.com
Neurocrine (NBIX) director sells 1,250 shares under Rule 10b5-1 plan - Stock Titan
Drug for uncontrollable movements eased symptoms in 94% of patients over 48 weeks - Stock Titan
Neurocrine reports positive INGREZZA data for TD in patients with IDD - grafa.com
Neurocrine presents data on tardive dyskinesia treatment - Investing.com
Neurocrine presents data on tardive dyskinesia treatment By Investing.com - Investing.com Australia
Doctors report TD reductions, better speech and socializing with INGREZZA - Stock Titan
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score - ChartMill
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
Neurocrine Biosciences Inc. (NBIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
Does Neurocrine Biosciences’ (NBIX) Rare Disease Push Quietly Rewire Its Endocrine Risk-Reward Profile? - simplywall.st
Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.50%
자본화:
|
볼륨(24시간):